Amicus Therapeutics Intangible Assets Over Time
| FOLD Stock | USD 10.13 0.30 3.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Amicus Therapeutics Performance and Amicus Therapeutics Correlation. Amicus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Intangible Assets Analysis
Compare Amicus Therapeutics and related stocks such as Incyte, Denali Therapeutics, and argenx NV ADR Intangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | 17 M | 8.2 M | 6.1 M | 0.0 | 16 M | 0.0 | 270.4 M | 236.9 M | 215.4 M | 193.8 M | 172.3 M | 150.8 M | 129.2 M | 123.5 M | 74.2 M |
| ARGX | 40.7 K | 15.6 K | 8.5 K | 8.5 K | 8.5 K | 7.7 K | 17.9 K | 15.6 K | 64.1 K | 45 M | 168 M | 171.7 M | 174.9 M | 125.2 M | 62.8 M |
| HRMY | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 162.3 M | 143.9 M | 161 M | 137.1 M | 148.8 M |
| RARE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 141.5 M | 129.2 M | 129 M | 131.1 M | 130.8 M | 160.1 M | 166.3 M | 108.7 M |
| RVMD | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 62 M | 60.9 M | 59.9 M | 58.8 M | 57.7 M | 48.3 M |
| LEGN | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 49 K | 5.1 M | 7.7 M | 4.7 M | 3.4 M | 4.1 M | 3.9 M |
| CYTK | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| DYN | 497 M | 271 M | 271 M | 108 M | 27 M | 102 M | 38 M | 25 M | 25 M | 25 M | 25 M | 25 M | 25 M | 22.5 M | 21.4 M |
| MREO | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 33 M | 32.6 M | 44.5 M | 31.6 M | 24.6 M | 24.1 M | 1.1 M | 1 M |
| BPMC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| AGIO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| BMRN | 11.7 M | 180.3 M | 163 M | 163.1 M | 156.6 M | 684 M | 553.8 M | 517.5 M | 491.8 M | 456.6 M | 417.3 M | 388.7 M | 338.6 M | 294.7 M | 244.4 M |
Amicus Therapeutics and related stocks such as Incyte, Denali Therapeutics, and argenx NV ADR Intangible Assets description
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.My Equities
My Current Equities and Potential Positions
| Amicus Therapeutics | FOLD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 10.13
Check out Amicus Therapeutics Performance and Amicus Therapeutics Correlation. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Amicus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.